Mohammed Imran1, Abul Kalam Najmi, Shams Tabrez. 1. Department of Pharmacology, Hamdard Institue of Medical Sciences and Research and Associated Hakeem Abdul Hameed Centenary Hospital, Jamia Hamdard, New Delhi-110062, India. drimran@aol.in.
Abstract
PURPOSE: To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel β3 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB). MATERIALS AND METHODS: We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, β3 receptor agonist and overactive bladder. RESULTS: Effect of Mirabegron on β3 adrenergic receptor purportedly releases nitric oxide(NO) by an increase in intracellular Ca2+ through accumulation of cyclic adenosine monophosphate (cAMP). Along with NO which relaxes the detrusor muscle, it also releases an urothelial-derived inhibiting factor (UDIF) that inhibits contractions. It increases the bladder capacity by causing bladder relaxation during the storage phase. CONCLUSION: Mirabegron appears to be a promising treatment in OAB patients by shifting its management from reducing detrusor over-activity to inducing relaxation. Also it lacks the troublesome side effects associated with the standard antimuscarinic management.
PURPOSE: To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel β3 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB). MATERIALS AND METHODS: We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, β3 receptor agonist and overactive bladder. RESULTS: Effect of Mirabegron on β3 adrenergic receptor purportedly releases nitric oxide(NO) by an increase in intracellular Ca2+ through accumulation of cyclic adenosine monophosphate (cAMP). Along with NO which relaxes the detrusor muscle, it also releases an urothelial-derived inhibiting factor (UDIF) that inhibits contractions. It increases the bladder capacity by causing bladder relaxation during the storage phase. CONCLUSION: Mirabegron appears to be a promising treatment in OABpatients by shifting its management from reducing detrusor over-activity to inducing relaxation. Also it lacks the troublesome side effects associated with the standard antimuscarinic management.
Authors: Mohamed G Soliman; Shawky A El-Abd; Ahmed M Tawfik; Mohamed H Radwan; Ahmed S El-Abd Journal: World J Urol Date: 2020-08-31 Impact factor: 4.226